Literature DB >> 2367529

Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs.

J H Axelrod1, M S Read, K M Brinkhous, I M Verma.   

Abstract

Primary skin fibroblasts from hemophilic dogs were transduced by recombinant retrovirus (LNCdF9L) containing a canine factor IX cDNA. High levels of biologically active canine factor IX (1.0 micrograms per 10(6) cells per 24 hr) were secreted in the medium. The level of factor IX produced increased substantially if the cells were stimulated by basic fibroblast growth factor during infection. Additionally, we also report that endothelial cells transduced by this virus can produce high levels of biologically active factor IX. We propose that skin fibroblasts and endothelial cells from hemophilia B dogs may serve as potential venues for the development and testing of models for treatment of hemophilia B by retrovirally mediated gene replacement therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2367529      PMCID: PMC54284          DOI: 10.1073/pnas.87.13.5173

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Bovine factor IX (Christmas factor).

Authors:  K Fujikawa; E W Davie
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

2.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production.

Authors:  A D Miller; C Buttimore
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

3.  Expression and linkage of genes for X-linked hemophilias A and B in the dog.

Authors:  K M Brinkhous; P D Davis; J B Graham; W J Dodds
Journal:  Blood       Date:  1973-04       Impact factor: 22.113

Review 4.  Medical complications of hemophilia.

Authors:  G C White; P M Blatt; C W McMillan; W P Webster; H R Lesesne; H R Roberts
Journal:  South Med J       Date:  1980-02       Impact factor: 0.954

5.  A simple assay for human factor IX: use of canine hemophilia B plasma as substrate.

Authors:  J C Goldsmith; K S Chung; H R Roberts
Journal:  Thromb Res       Date:  1978-03       Impact factor: 3.944

6.  Complications of combined surgery and radiation therapy for carcinoma of the endometrium.

Authors:  J C Remy; R G Fruchter; J Boyce; M Macasaet; K Choi; M Rotman
Journal:  Int J Gynaecol Obstet       Date:  1985-04       Impact factor: 3.561

7.  3,3',5,5' - Tetramethylbenzidine as an Ames test negative chromogen for horse-radish peroxidase in enzyme-immunoassay.

Authors:  E S Bos; A A van der Doelen; N van Rooy; A H Schuurs
Journal:  J Immunoassay       Date:  1981

8.  Expression of human alpha-globin and mouse/human hybrid beta-globin genes in murine hemopoietic stem cells transduced by recombinant retroviruses.

Authors:  C L Li; V J Dwarki; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

9.  A monoclonal antibody to factor IX that inhibits the factor VIII:Ca potentiation of factor X activation.

Authors:  S P Bajaj; S I Rapaport; S L Maki
Journal:  J Biol Chem       Date:  1985-09-25       Impact factor: 5.157

10.  The gene structure of human anti-haemophilic factor IX.

Authors:  D S Anson; K H Choo; D J Rees; F Giannelli; K Gould; J A Huddleston; G G Brownlee
Journal:  EMBO J       Date:  1984-05       Impact factor: 11.598

View more
  13 in total

1.  Adhesion and incorporation of lacZ-transduced endothelial cells into the intact capillary wall in the rat.

Authors:  L M Messina; R M Podrazik; T A Whitehill; D Ekhterae; T E Brothers; J M Wilson; W E Burkel; J C Stanley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

2.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1990-10-25       Impact factor: 16.971

Review 3.  Prospects for gene therapy in sports medicine.

Authors:  T G Gerich; F H Fu; P D Robbins; C H Evans
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  1996       Impact factor: 4.342

Review 4.  The function of dog models in developing gene therapy strategies for human health.

Authors:  Keri L Nowend; Alison N Starr-Moss; Keith E Murphy
Journal:  Mamm Genome       Date:  2011-07-06       Impact factor: 2.957

5.  Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.

Authors:  L Wang; K Takabe; S M Bidlingmaier; C R Ill; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 6.  Gene therapy vectors as drug delivery systems.

Authors:  S A Afione; C K Conrad; T R Flotte
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

7.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 8.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

9.  Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo.

Authors:  Y Dai; M Roman; R K Naviaux; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

10.  Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants.

Authors:  R Scharfmann; J H Axelrod; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.